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Abstract
Background: Inflammation plays a critical role in lung disease development and progression in
cystic fibrosis. Azithromycin is used for the treatment of cystic fibrosis lung disease, although its
mechanisms of action are poorly understood. We tested the hypothesis that azithromycin
modulates lung inflammation in cystic fibrosis mice.
Methods: We monitored cellular and molecular inflammatory markers in lungs of cystic fibrosis
mutant mice homozygous for the ΔF508 mutation and their littermate controls, either in baseline
conditions or after induction of acute inflammation by intratracheal instillation of
lipopolysaccharide from Pseudomonas aeruginosa, which would be independent of interactions of
bacteria with epithelial cells. The effect of azithromycin pretreatment (10 mg/kg/day) given by oral
administration for 4 weeks was evaluated.
Results: In naive cystic fibrosis mice, a spontaneous lung inflammation was observed, characterized
by macrophage and neutrophil infiltration, and increased intra-luminal content of the pro-
inflammatory cytokine macrophage inflammatory protein-2. After induced inflammation, cystic
fibrosis mice combined exaggerated cellular infiltration and lower anti-inflammatory interleukin-10
production. In cystic fibrosis mice, azithromycin attenuated cellular infiltration in both baseline and
induced inflammatory condition, and inhibited cytokine (tumor necrosis factor-α and macrophage
inflammatory protein-2) release in lipopolysaccharide-induced inflammation.
Conclusion: Our findings further support the concept that inflammatory responses are
upregulated in cystic fibrosis. Azithromycin reduces some lung inflammation outcome measures in
cystic fibrosis mice. We postulate that some of the benefits of azithromycin treatment in cystic
fibrosis patients are due to modulation of lung inflammation.
Published: 25 October 2006
Respiratory Research 2006, 7:134 doi:10.1186/1465-9921-7-134
Received: 26 May 2006
Accepted: 25 October 2006
This article is available from: http://respiratory-research.com/content/7/1/134
© 2006 Legssyer et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 13
(page number not for citation purposes)
Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/134Background
Cystic fibrosis (CF) is the most common, life-threatening,
recessively inherited disease in Caucasian populations. CF
results from mutations affecting a single gene encoding
the CF transmembrane conductance regulator (CFTR)
protein [1,2], which functions as a cyclic AMP-dependent
low conductance chloride channel [3] but also has effects
on the activity of other ion channels [4-6]. The most com-
mon CF mutation results in deletion of a single phenyla-
lanine residue at position 508 (ΔF508) and causes
defective synthesis and folding of the mutant protein that
fails to transit from the endoplasmic reticulum and reach
the apical membrane of many epithelial cell types [7]. CF
has a complex phenotype with variable disease severity
and multiple clinical manifestations including high con-
centrations of sweat electrolytes, exocrine pancreatic
insufficiency, male infertility and sino-pulmonary disease
[8]. The lung disease in CF is characterized by a self-sus-
taining cycle of airway obstruction, inflammation and
infection. The high morbidity and mortality in CF is due
to chronic respiratory infection, culminating in coloniza-
tion with Pseudomonas aeruginosa, which has been impli-
cated as an important stimulus in the progression of lung
disease. This devastating complication, characterized by
chronic unopposed neutrophil-dominated inflammation
and progressive bronchiectasis, increases rates of lung
function decline [9] and is a significant predictor of mor-
tality [10].
Active treatment of lung disease is a cornerstone of CF
management. This may include anti-inflammatory ther-
apy approaches in combination with other conventional
therapies such as antibiotics [11,12]. Azithromycin, a
macrolide antibiotic structurally modified from erythro-
mycin, has been used to treat CF patients resulting in sig-
nificant clinical improvement in lung function with a
reduction in pulmonary exacerbations and fewer courses
of antibiotic use [13-16]. The precise mechanism of action
of macrolides, apart from their antibactericidal actions
[17-20], remains unclear. We hypothesized that azithro-
mycin modulates lung inflammation in CF. We examined
the effect of azithromycin pre-treatment on cellular and
molecular parameters in the lungs of CF and normal
homozygous wild-type mice with or without challenge
with lipopolysaccharide from Pseudomonas aeruginosa
(LPS), which would be independent of interactions of
bacteria with epithelial cells [21-23].
Methods
Animal model
Young adult female CF mice homozygous for the ΔF508
mutation in the 129/FVB outbred background [24] and
their wild-type littermates were housed in static isolator
cages at the animal care specific pathogen free facility of
the University of Louvain following recommendations of
the Federation of European Laboratory Animal Science
Associations (FELASA) [25]. In order to prevent intestinal
obstruction CF mice were weaned to a liquid diet (Pepta-
men®, Nestlé Clinical Nutrition, France). Peptamen was
replaced daily. Non-CF mice were fed with standard diet
(Pavan Service-Carfil, Oud-Tournhout, Belgium) changed
out once a week when cages were then sanitized and fur-
nished with fresh bedding. Demineralized and acidified
water was supplied ad libitum. The genotype of each ani-
mal was checked at 21 days of age using Taqman quanti-
tative PCR multiplex analysis (Taqman, ABI PRISM® 7700
Sequence Detection System, Applied Biosystems, Foster,
CA, USA) of tail clip DNA. Primers and Minor Groove
Binder (MGB) probes designed for allele specific PCR
using Primer Express Software (Applied Biosystems, Fos-
ter City, CA, USA) were as follows: forward primer = 5'-
TTTCTTGGATTATGCCGGGTA-3'; reverse prime = 5'-GTT-
GGCAAGCTTTGACAACACT-3'; wild-type specific probe
= 5'-FAM-AAACACCAAAGATGATATT-MGB-3'; mutant
specific probe = 5'-VIC-AACACCAATAATATTTTC-MGB-
3'. These studies and procedures were approved by the
local Ethics Committee for Animal Welfare and con-
formed to the European Community regulations for ani-
mal use in research (CEE n° 86/609).
Induction of lung inflammation
Sex and weight-matched CF and normal homozygous
wild-type mice, 10 to 14 weeks of age, pre-treated with
azithromycin (Pfizer, Brussels, Belgium) (10 mg/kg body
weight/day, for 4 weeks, by oral administration using a
pipette) and controls without azithromycin treatment
were anesthetized with an i.p. mixture of 100 mg/kg keta-
mine (Parke-Davis, Ann Arbor, MI, USA) and 15 mg/kg
xylazine (Bayer, Leverkusen, Germany). Acute lung
inflammation was induced by instillation into the trachea
through the mouth, using a laryngoscope and fine pipette
tip, of 10 μg/20 g body weight of LPS (Sigma Chemical, St.
Louis, MO, USA) in 50 μl saline [26]. Azithromycin treat-
ment was stopped when LPS was administered.
Bronchoalveolar lavage (BAL)
At selected time points after LPS instillation, mice were
killed by i.p. injection of 20 mg sodium pentobarbital
(Abbott, Chicago, IL, USA). BAL was performed by cannu-
lating the trachea and lavaging with 1 ml sterile saline as
described [27]. The BAL fluid (BALF) was centrifuged (250
× g, 10 min, 4°C) and the supernatant was aliquoted and
stored at -20°C for further biochemical measurements.
Differential cell counts were performed on cytospin prep-
arations using DiffQuick staining (Dade, Brussels, Bel-
gium).Page 2 of 13
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Myeloperoxidase (MPO) activity
After BAL was performed, lungs were perfused via the right
ventricle with saline and excised. MPO activity in lung
homogenates was assessed at 490 nm over 10 min as pre-
viously described [28].
Lactate dehydrogenase (LDH) activity
LDH activity in BALF samples was assessed spectrophoto-
metrically as described elsewhere [29].
Cytokine assays
Mouse macrophage inflammatory protein (MIP)-2, (R&D
Systems, Minneapolis, MN, USA), tumor necrosis factor
(TNF)-α and IL-10 (BD Pharmingen, San Diego, CA, USA)
concentrations were measured in BALF using a standard
sandwich enzyme-linked immunosorbent assay (ELISA)
following the respective manufacturer's protocols. The
detection limits of these ELISAs were respectively 1.5; 7.5
and 15.6 pg/ml. Biochemical analyses were performed in
duplicate for each sample.
Histopathology
Nonlavaged whole lungs were excised and inflation fixed
via the trachea in 4% buffered paraformaldehyde and
processed at 5 μm thickness for light microscopy. Slides
were stained with hematoxilin and eosin or with Masson
trichrome stain.
Bacteriology
BALF samples were plated onto Columbia agar base with
5% sheep blood, a polyvalent non-selective medium. Sab-
ouraud agar (Becton Dickinson, Franklin Lakes, NJ, USA)
and Mac Conkey culture media were used to select for
yeasts and fungi and for Gram negative bacteria, respec-
tively. Plates were placed in a traditional incubator at
35°C for a minimum of 24 h. All tests were performed in
duplicate.
Statistics
Results are expressed as means ± SEM. Statistical data were
analysed using SAS-JMP software (SAS Institute, Cary, NC,
USA). Between-group comparisons were evaluated using
one-way analysis of variance. Posthoc comparisons were
made using Student's t test or Tukey-Kramer HSD test, as
appropriate. Null hypothesis was rejected at p < 0.05. The
alpha level was adjusted following Benferroni correction
for pooled data from different experiments after identify-
ing that means of normally distributed variables are not
different (t test) and variances of populations are homo-
geneous (Snedecor's F test).
Results
Spontaneous lung inflammatory status in CF mice
Repeated bacteriological examination of BALF samples
from CF and normal homozygous wild-type mice showed
no known pathogenic infectious agents cultured in poly-
valent media, and zero growth detected in selective cul-
ture media for yeast and fungus and for Gram negative
bacteria (not shown). However, a spontaneous inflamma-
tory status was observed in lungs of naive or not experi-
mentally manipulated CF mice. Cellular profile in BALF
samples from naive CF and wild-type mice showed strik-
ing differences in total and differential cell counts (Fig.
1A). As illustrated in Table 1 for animals not treated with
azithromycin, the total number of cells was significantly
higher in CF in comparison with wild-type mice. Macro-
phage counts were significantly higher in BALF samples
from CF in comparison with wild-type mice (Fig. 1A,
Table 1). Likewise, a spontaneous neutrophilia was
observed in all of the 13 naive CF mice examined in two
different experiments whereas it was always undetectable
in naive wild-type mice (Table 1). MPO activity, an indi-
cator of neutrophilic recruitment and activation status,
was significantly increased in lung homogenates from
naive CF mice (Fig. 1B). Moreover, LDH activity, an indi-
cator of tissue injury, showed a significant increase in
BALF samples from naive CF when compared to wild-type
mice (Fig. 1C). MIP-2, a key chemokine in the recruitment
of neutrophils functionally equivalent to the human IL-8,
was about two-fold higher in naive CF than in wild-type
mice. In the experiment illustrated in Fig. 2A, MIP-2
ranged from 2.9 to 6.5 pg/ml and from 1.5 to 3.5 pg/ml
in naive CF and wild-type animals, respectively. Only one
of the 9 CF animals showed a MIP-2 value within the
range of those measured in control animals. No signifi-
cant difference was seen between the two groups of ani-
mals with respect to concentrations of TNF-α (Fig. 2B; p:
0.21) and the anti-inflammatory cytokine IL-10 (Fig. 2C;
p: 0.07).
Histological findings confirmed the presence of spontane-
ous lung inflammation in naive CF mice. In contrast with
age-matched wild-type littermates (Fig. 3A), focal areas of
acute leukocytic bronchopneumonia were seen in lung
sections from naive CF mice (Fig. 3B). Examination of
Masson's trichrome sections showed no gross histologic
evidence of increased collagen deposition in naive CF
mice aged of 10–14 weeks when compared to wild-type
animals (not shown).
Exaggerated cell response to acutely LPS-induced 
inflammation in CF mice
We next assessed the amplitude of pulmonary responses
to LPS from P aeruginosa in CF and in wild-type mice.
Intratracheal instillation of LPS was generally well toler-
ated by both mutant and normal animals, and no mortal-Page 3 of 13
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after 24 h and 48 h in LPS treated animals without any sig-
nificant difference between wild-type and CF mice. After
LPS exposure, a time-dependent cell infiltration was evi-
dent in both CF and wild-type mice. Macrophage num-
bers in BAL fluid were below control levels at 3 h and 24
h before coming back to baseline at 48 h postchallenge
(Fig. 4A). The progressive and massive increase in neu-
trophil numbers was preceded by increase in MPO activity
(Fig. 4B–C). Interestingly, the effect of LPS administration
on cellular responses appeared to be different in CF com-
pared to wild-type mice. At 48 h, the extent of both mac-
rophage (Fig. 4A) and neutrophil count (Fig. 4B) was
about two-fold higher in CF than in wild-type mice. The
more exuberant neutrophil recruitment in CF mice was
confirmed by monitoring the determination of MPO
activity (Fig. 4C). In both groups of animals the enzyme
activity continued to increase during 48 h being highest at
the last time point evaluated when similar values were
then noted in the two groups. However, at 24 h, a twice-
higher level of MPO activity was reached in CF when com-
pared to wild-type mice. No significant difference
between the two groups of animals was seen on the LDH
response after LPS treatment although a trend toward
higher values was found at 24 h.
Different LPS induced cytokine release patterns in CF and 
control mice
Differences in the patterns of LPS-induced cytokine
responses were revealed between the two groups of ani-
mals (Fig. 5A–C). A rapid release of MIP-2 (Fig. 5A) and
TNF-α (Fig. 5B) was observed at 3 h after LPS instillation
in wild-type and CF mice. At 24 h after LPS administra-
tion, when pro-inflammatory cytokine release responses
progressively declined, MIP-2 levels remained signifi-
cantly higher in CF than in wild-type mice (Fig. 5A). IL-10
production was not detectable at 3 h and 24 h after LPS
challenge in both normal and mutant mice. However, at
48 h IL-10 was significantly reduced in CF animals com-
pared to wild-type mice (Fig. 5C).
Effect of azithromycin on the inflammatory response
To determine whether the use of azithromycin may reduce
inflammatory responses in CF, we tested its activity in our
animal model. Long-term (4 weeks), low dose (10 mg/kg
body weight/day, by oral administration) azithromycin
pre-treatment was performed in CF and wild-type mice
either in baseline conditions or in LPS-induced inflamma-
tion. Azithromycin treatment reduced BALF macrophage
numbers in CF mice treated as compared to those CF ani-
mals untreated with the macrolide (Table 1). MPO activ-
ity in lung homogenates and neutrophil infiltrate in BALF
samples were also reduced, although the latter marker did
not reach statistical significance. In contrast, in naive wild-
type mice no effect of azithromycin was seen on cytotox-
icity markers. Assessment of cytokine release did not show
any noticeable effect of azithromycin in naïve CF mice
(Table 2). In naive wild-type mice a marked increase of IL-
10 level was noted after azithromycin treatment (Table 2).
Azithromycin treatment significantly reduced BALF cellu-
larity in CF mice after LPS challenge (Table 3). At 48 h
Cell composition of the bronchoalveolar lavage fluid (BALF) and tissue markers of lung inflammati n from CF and wild-type (WT) mice under baseline conditionsFigure 1
Cell composition of the bronchoalveolar lavage fluid (BALF) 
and tissue markers of lung inflammation from CF and wild-
type (WT) mice under baseline conditions. (A) alveolar mac-
rophages and neutrophil cell counts in BALF; (B) myeloper-
oxidase (MPO) activity in lung homogenates, expressed as 
optical density (OD) × 10-3/second; (C) lactate dehydroge-
nase (LDH) activity in BALF, expressed as U/L. Values are 
means ± SEM for 6–9 animals per group. *p < 0.05; †p < 0.01 
for comparison of corresponding mean value vs. that 
obtained for the same parameter in the wild-type group of 
mice.
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infiltrate was significantly decreased in CF mice pre-
treated with azithromycin as compared to those CF ani-
mals without macrolide pre-treatment. At 24 h, the neu-
trophil count was reduced by half in azithromycin pre-
treated CF mice as compared with the untreated CF group.
In CF mice, pre-treatment with azithromycin significantly
reduced MPO activity 48 h after LPS (Table 3) when levels
similar to those observed in naive conditions were
reached (Table 1). No significant effect on LDH activity
was observed following azithromycin treatment in LPS
treated CF mice although a trend toward lower values was
observed at 24 h and 48 h after LPS (Table 3). No similar
effect of azithromycin on cell recruitment or MPO activity
was noted in wild-type mice at any time point after LPS
instillation (Table 3).
Significant effects of azithromycin treatment on LPS-
induced cytokine release were noticeable in CF mice,
notably on TNF-α at 3 h and 48 h (Table 4). At 24 h after
LPS instillation, the MIP-2 response was reduced follow-
ing pre-treatment with the macrolide (Table 4). Azithro-
mycin did not modify the levels of IL-10 in CF mice 48 h
after LPS (Table 4). In normal mice, TNF-α and MIP-2
responses were not modified after azithromycin pre-treat-
ment in wild-type as they were in CF mice.
Discussion
The present study was designed to explore the hypothesis
that azithromycin modulates lung inflammation in CF.
The growing interest in macrolide antibiotics as beneficial
agents in CF followed the success of long-term erythromy-
cin in the treatment of diffuse pan-bronchiolitis, a condi-
tion that exhibits striking similarities to CF [30-32]. It has
been suggested that macrolides might exert their effect by
normalizing ion transport across the CF respiratory epi-
thelium [33]. However, it has been clearly demonstrated
that the apparent beneficial effects of these drugs on pul-
monary outcome in CF are not mediated by modulation
of ion transport [34]. An open-label study [35] concluded
that neither up-regulation of multi-drug resistance or
CFTR proteins nor reduced bacterial adherence appear to
be significant contributing mechanisms accounting for
the beneficial results in clinical trials of macrolides in CF.
We show that treatment with the macrolide in CF mice
attenuated cellular infiltration in spontaneous and
induced inflammatory conditions and inhibited pro-
inflammatory cytokine release in LPS-induced inflamma-
tion.
We show that, in the absence of any detectable bacterial
and fungal infection, young adult female CF mice gener-
ated in the 129/FVB background and homozygous for the
most common CFTR gene mutation ΔF508 exhibit a spon-
taneous lung inflammatory status. The inflammation,
confirmed histologically, is characterized by increased
lung accumulation of macrophages and neutrophils,
combined with upregulation of the pro-inflammatory
cytokine MIP-2. This is associated with a higher degree of
LDH activity, a biomarker of tissue damage. It has been
reported that murine models of CF typically exhibit a
range of severe and fatal intestinal pathologies but fail to
develop significant CF like lung disease spontaneously
[36-40]. However, Durie et al [41] have demonstrated age-
related lung interstitial thickening and fibrosis in cftr-
knockout mice. Spontaneous inflammation [42,43],
excessive inflammatory responses and/or defective bacte-
rial clearance after infection with P aeruginosa [44-49]
have been reported in several CF mouse models. It has
been postulated that the lack of spontaneous lung disease
in most Cftr-knockout mouse strains, with the exception
of a C57Bl/6 backcrossed strain, is related to the presence
of an alternative (Calcium dependent) chloride channel
function [42]. In agreement with the highly complex
nature of CF lung pathology, phenotypic differences in CF
mouse models have been observed relating to multiple
factors such as the specific mutation, genetic background
and environmental factors [45]. We show that while bac-
Table 1: Cell composition of the bronchoalveolar lavage fluid and enzyme markers of lung inflammation from CF and wild-type (WT) 
mice in the absence of induction with P aeruginosa LPS, with and without pre-treatment with azithromycin (10 mg/kg/day), by oral 
administration, for 4 weeks.
Alveolar Macrophages × 104/ml Neutrophils × 104/ml MPO OD × 10-3/
second
LDH U/L
CF AZM- 29.7 ± 4.2 2.8 ± 1.9 11.3 ± 1.2 108.7 ± 21.1
AZM+ 19.8 ± 1.5* 0.6 ± 0.4 7.7 ± 1.0* 91.8 ± 21.0
WT AZM- 8.6 ± 1.4 0.0 ± 0.0 3.7 ± 0.7 67.6 ± 22.3
AZM+ 12.8 ± 1.5 0.0 ± 0.0 3.6 ± 0.4 70.6 ± 12.4
Values are means ± SEM for 9–13 animals per each of the 4 subgroups from pooled data obtained from two different sets of experiments. * p < 
0.025 for comparison of corresponding mean value vs. that obtained for the same parameter in the same group of animal without pre-treatment 
with azithromycin.Page 5 of 13
(page number not for citation purposes)
Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/134teriological studies have ruled out common bacteria and
fungi, a possible involvement of a viral infection could
not be excluded.
Irrespective of the presence of bacteria or other microor-
ganisms, hypersusceptibility to environmental conditions
between CF and wild-type mice could play a role in the
spontaneous inflammatory status we found in naive CF
mice. It was reported that knockout CF mice are more sus-
ceptible than normal homozygous and heterozygous
mice to environmental P aeruginosa provided by non-ster-
ile drinking water [49]. However, in our work, sterilised
liquid diet was replaced daily; moreover, proper animal
husbandry facilities including a self-contained microbio-
logical unit with preventive measures and health monitor-
ing were ensured following the FELASA recommendations
for experimental units of laboratory animals established
in our institution [25]. Possible nutritional differences, i.e.
malnutrition, between cftr-knockout mice and wild-type
mice were reported as being related to excessive inflam-
mation in CF [50]. Nevertheless, van Heeckeren et al [51]
found that dietary effects, such as Peptamen, are unlikely
to account for differences in inflammatory responses to
lung infection with mucoid P aeruginosa.
Our present data, showing spontaneous inflammation in
naive CF mutant mice, appear to support clinical and
experimental studies [52-55] suggesting that inflamma-
tion is a very early event and may occur even in the
absence of bacterial pathogens. However, in a recent study
it was claimed that in CF infants inflammation is a
response to current or previous infection [56]. Whether
CFTR dysfunction results directly in an increased predis-
position to infection and whether inflammation arises
independently from infection remains to be established.
The characterization of a CF animal model expressing
spontaneous lung disease and displaying exaggerated
immune responses after induction of acute inflammation
may represent an interesting preclinical model of disease
and a useful in vivo system to assist in dissecting the patho-
genesis of CF lung disease. The fact that our mouse model
harbors a specific clinically relevant mutation represents
an additional advantage for studying novel therapeutic
strategies aiming at correcting intracellular trafficking and
activation of the protein.
Spontaneous lung accumulation of neutrophils in our
naive CF mutant mice is likely to be related to the elevated
intra-luminal content of the chemo-attractant MIP-2.
These data are in agreement with clinical [52-54,57,58]
and experimental [55,59-61] studies suggesting that IL-8
levels are increased in CF. Blood neutrophils from
patients with CF spontaneously secrete higher amounts of
IL-8 [62]. Overall, neutrophil-derived toxic products may
contribute to lung damage [63-65]. The degree of MPO
activity in sputum has been positively correlated with air-
way injury and airflow obstruction in CF patients [66,67].
LDH activity, classically used to evaluate safety of agents
analysed in different in vitro or in vivo experimental condi-
tions [68], is increased in our naive CF mice indicating a
higher index of cell injury.
Inflammatory cytokine concentrations in airways from CF and wild- ype (WT) mi e unde  baseline conditionsFigure 2
Inflammatory cytokine concentrations in airways from CF 
and wild-type (WT) mice under baseline conditions. (A) 
macrophage inflammatory protein-2 (MIP-2); (B) tumor 
necrosis factor-alpha (TNF-α); (C) interleukin (IL)-10. Val-
ues, expressed as pg/ml, are means ± SEM for 6–9 animals 
per group from the same experiment as that used to gener-
ate Figure 1. *p < 0.001 for comparison of corresponding 
mean value vs. that obtained in the wild-type group of mice.
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Hematoxylin and eosin-stained lung sections obtained from: (A-B) a naive wild-type mouse showing no pathological abnormali-ties; (C-D) a naive CF mouse showing focal areas of bronchopneumo ia with neutrophil infiltratio  (arrow in C; focus enlarged at D)Figure 3
Hematoxylin and eosin-stained lung sections obtained from: (A-B) a naive wild-type mouse showing no pathological abnormali-
ties; (C-D) a naive CF mouse showing focal areas of bronchopneumonia with neutrophil infiltration (arrow in C; focus enlarged 
at D). Arrowheads identify neutrophils in the bronchial lumen at D and in the inset; bronchial epithelial cells are identified by 
arrows. Calibration bars correspond to 50 μm in panels A-D and to 25 μm in the inset.
Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/134The enhanced alveolar macrophages infiltrate observed in
naive CF mice may play a major role in lung inflamma-
tion in CF. An activated status of alveolar macrophages
may contribute to the triggering and development of
inflammation in CF lung pathology. Accordingly, immu-
nocytochemistry studies have demonstrated a higher per-
centage of CF than control alveolar macrophages
expressing intracellular pro-inflammatory cytokines, IL-6
and IL-8 [59].
It has been proposed that CFTR is a cellular receptor for
binding, endocytosing and clearing P aeruginosa from the
normal lung [21-23]. In order to investigate inflammatory
responses independently of alterations in clearance of the
Time course of cytokine release in bronchoalveolar lavage fluid obtain d 3 h, 24 h and 48 h after intratr chea  instillation of P aerugi osa LPS from CF and wild-type (WT) miceF gur  5
Time course of cytokine release in bronchoalveolar lavage 
fluid obtained 3 h, 24 h and 48 h after intratracheal instillation 
of P aeruginosa LPS from CF and wild-type (WT) mice. (A) 
macrophage inflammatory protein-2 (MIP-2); (B) tumor 
necrosis factor-alpha (TNF-α); (C) interleukin (IL)-10. Val-
ues, expressed as pg/ml, are means ± SEM for 6–9 animals 
per each of the 8 subgroups from the same experiment as 
that used to generate Figure 4. *p < 0.05; †p < 0.001; ‡p < 
0.0005 for comparison of corresponding mean value vs. that 
obtained at the same time point in the wild-type group of 
mice.
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Time course of cell and tissue components of the inflamma-tory response in bro choalveolar lavag  fluid obta ed 3 h, 24 h and 48 h aft  intra racheal instillation f P aeruginosa LPS f om CF and wild-type (WT) miceF gu  4
Time course of cell and tissue components of the inflamma-
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Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/134bacteria, we used, in the present work, intratracheal LPS as
a challenge. As previously reported when using a model of
LPS-induced lung inflammation in mice [69], macro-
phage numbers in BAL fluid were initially below control
levels before coming back later on to baseline levels. Nev-
ertheless, reasons why LPS treatment reduced early alveo-
lar macrophage response are not clear. We could speculate
that activation of pre-existing alveolar macrophages could
result in increased cell adherence to the bronchoalveolar
wall and cell attachment to the interstitial lung tissue
making it more difficult to recover the cells during lavage
procedure. Another possible indirect mechanism could be
that during the early phase, some degree of bronchocon-
striction secondary to LPS might contribute to technical
difficulties in recovering alveolar macrophages during lav-
age. After LPS, effect on MPO activity preceded that on
neutrophil count suggesting that LPS could initially act
rather by increasing cell activation status. As previously
described following aerosolisation of LPS from P aerugi-
nosa, cellular and molecular responses were exaggerated in
CF mice [70], suggesting that the latent inflammatory
imbalance in CF may contribute to exert higher sensitivity
to acute inflammatory responses [55]. Instillation of LPS
into the trachea [26] allows delivery of accurate amounts
of substance into the lungs. Indeed, by this method,
smaller amounts of LPS, 1,000 lower than those previ-
ously described [70] were used in this work. It has been
recently demonstrated in a selected CF mouse strain [47]
that CFTR deficiency should be sufficient to produce
increased inflammatory responses to a free-living mucoid
P aeruginosa administered by insufflation into the lung.
We show here more prominent release of pro-inflamma-
tory cytokine MIP-2 in CF as compared with wild-type
mice after acutely induced inflammation with LPS.
Downregulation of IL-10 may also be responsible for pro-
longed and excessive inflammatory responses in CF
patients [59,71-73]. In our experiments we found reduced
levels of IL-10 in the BALF of CF mice at 48 h after LPS
challenge. In murine models relevant to CF lung disease,
reduced levels of IL-10 have been associated with
increased neutrophil infiltrate and increased activation of
the transcriptional nuclear factor κB, NF-κB, in response
to P. aeruginosa infection [74-76]. Exogenous IL-10
administration attenuated these excessive responses [76]
suggesting that reduction of the anti-inflammatory
cytokine expression may be responsible for prolonged
and excessive inflammatory response in CF. Events
involved in imbalance of inflammatory cytokines in CF
lung disease are poorly understood and may include
Table 3: Cell composition of the bronchoalveolar lavage fluid and enzyme markers of lung inflammation from CF and wild-type (WT) 
mice at the indicated time points after a single dose of P aeruginosa LPS with and without pre-treatment with azithromycin (10 mg/kg/
day), by oral administration, for 4 weeks.
Alveolar Macrophages × 104/ml Neutrophils × 104/ml MPO OD × 10-3/second LDH U/L
CF LPS 3 h AZM- 7.9 ± 0.6 0.6 ± 0.1 21.2 ± 4.2 50.0 ± 11.5
AZM+ 3.6 ± 0.7† 0.4 ± 0.2 30.1 ± 4.7 52.6 ± 17.6
LPS 24 h AZM- 6.4 ± 0.9 130.9 ± 7.9 51.7 ± 3.7 186.0 ± 61.2
AZM+ 6.4 ± 0.7 66.4 ± 10.3† 44.8 ± 3.3 98.2 ± 30.5
LPS 48 h AZM- 38.2 ± 4.3 232.9 ± 31.9 58.8 ± 8.2 155.6 ± 31.5
AZM+ 26.7 ± 2.4* 192.2 ± 27.0 15.4 ± 3.4‡ 128.7 ± 21.8
WT LPS 3 h AZM- 5.0 ± 0.9 0.7 ± 0.1 17.7 ± 1.1 49.8 ± 20.6
AZM+ 4.4 ± 0.5 1.7 ± 0.9 21.4 ± 2.0 44.0 ± 6.7
LPS 24 h AZM- 5.0 ± 1.7 93.3 ± 23.3 25.8 ± 1.6 55.0 ± 22.3
AZM+ 7.1 ± 1.7 116.4 ± 22.7 31.2 ± 3.4 70.6 ± 18.6
LPS 48 h AZM- 15.7 ± 4.4 142.3 ± 25.7 64.9 ± 8.6 168.2 ± 25.3
AZM+ 14.1 ± 2.1 146.5 ± 17.0 54.9 ± 4.9 160.8 ± 19.1
Values are means ± SEM for 6–9 animals per each of the 12 subgroups. *p < 0.05; †p < 0.005; ‡p < 0.0005 for comparison of corresponding mean 
value vs. that obtained for the same parameter at the same time point without pre-treatment with azithromycin.
Table 2: Inflammatory cytokine and chemokine concentrations 
in airways from CF and wild-type (WT) mice in the absence of 
induction with P aeruginosa LPS, with and without pre-
treatment with azithromycin (10 mg/kg/day), by oral 
administration, for 4 weeks.
MIP-2 pg/ml TNF-α pg/ml IL-10 pg/ml
CF AZM- 4.9 ± 0.4 11.8 ± 1.8 84.2 ± 13.9
AZM+ 5.4 ± 0.7 9.3 ± 1.6 68.1 ± 7.9
WT AZM- 2.9 ± 0.3 8.1 ± 1.6 42.3 ± 12.1
AZM+ 3.7 ± 0.4 10.6 ± 2.1 103.0 ± 19.1*
Values are means ± SEM for 9–13 animals per each of the 4 subgroups 
from pooled data obtained from the same sets of experiments as 
those used to generate Table 1. * p < 0.025 for comparison of 
corresponding mean value vs. that obtained for the same parameter in 
the same group of animal without pre-treatment with azithromycin.Page 9 of 13
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Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/134upregulation of NFκB [77], which modulates a large
number of genes, particularly those involved in immune,
inflammatory and anti-apoptotic responses [78,79].
Our data showed that in CF mutant animals, but not in
normal animals, pre-treatment with azithromycin reduces
the macrophage count in BALF before and after LPS chal-
lenge. It is well known that macrolides accumulate in the
epithelial lining fluid of respiratory tract and easily enter
the host defence cells, predominantly macrophages and
neutrophils [80]. Direct correlations between neutrophil
count and MPO activity seemed to be difficult to draw
particularly while analysing combined time-dependent
responses to LPS and azithromycin treatment when mul-
tiple pro-inflammatory and anti-inflammatory processes
are playing simultaneously. Inhibition of neutrophil
recruitment at 24 h after LPS in macrolide pre-treated CF
mice could result, at least partly, from inhibition of neu-
trophil migration via reduction in pro-inflammatory
cytokine MIP-2. A significant reduction in MPO activity
was observed at 48 h after LPS exposure.
We observed a down-regulation of inflammatory
cytokines (TNF-α and MIP-2) by azithromycin in CF mice.
This may be related to results of a preliminary clinical trial
in which reduction in sputum IL-8 levels was noted in 4
of the 6 patients treated with erythromycin [81]. In nor-
mal mice, azithromycin had no effect on cell infiltration
and on pro-inflammatory cytokines, but increased IL-10
levels. Our results differ from those reported from an in
vivo control mouse model of chronic endobronchial infec-
tion in response to mucoid Pseudomonas beads, in which
macrolide treatment resulted in reduction of neutrophil
infiltration and pro-inflammatory cytokines [82]. In con-
trast to our experimental conditions in which inflamma-
tion was investigated in the absence of infection, the effect
of azithromycin could also be mediated by interactions
with multiple virulence factors influencing the bacterial
pathogenicity [82]. Accordingly, an in vitro study has sug-
gested that the action of azithromycin could be mediated
by interactions with the outer membrane of the bacteria
[20]. Increased IL-10 levels following treatment with azi-
thromycin in wild-type mice might contribute to an anti-
inflammatory action of the macrolide. Yet, azithromycin
did not increase IL-10 levels in CF mice. Although gener-
ally recognized as exerting a protective role, some evi-
dence indicates that production of this pleiotropic
cytokine can also lead to undesirable effects during
inflammation and infection. Accordingly, administration
of anti-IL-10 has been shown to enhance the survival in a
murine model of Klebsiella pneumoniae infection [83].
Moreover, IL-10 production has been observed to be det-
rimental in lung function with Streptococcus pneumoniae in
mice [84]. Since macrolide antibiotics exhibit their anti-
microbial activities by interfering with the protein produc-
tion of microorganisms, interference with protein
production may be one mechanism by which cytokine
release might be influenced by these drugs. Inhibition of
cytokine production might also result from a modulation
of gene expression. As downregulating effects of azithro-
mycin are evident on pro-inflammatory cytokine release
responses in CF mice, we could postulate that the mac-
rolide exerts its action in CF lung disease on inhibiting
TNF-α release and in less extent MIP-2, possibly by inhib-
iting NFκB pathway.
Conclusion
Our results support the use of this CF mouse model as a
valuable tool for studying human CF lung disease. This
study further supports the concept that inflammation is a
Table 4: Inflammatory cytokine concentrations in airways from CF and wild-type (WT) mice at the indicated time points after a single 
dose of P aeruginosa LPS with and without pre-treatment with azithromycin (10 mg/kg/day), by oral administration, for 4 weeks.
MIP-2 pg/ml TNF-α pg/ml IL-10 pg/ml
CF LPS 3 h AZM- 3966.7 ± 230.3 4041.1 ± 347.6 ND
AZM+ 3800.8 ± 106.2 2648.1 ± 386.3* ND
LPS 24 h AZM- 489.1 ± 20.4 282.3 ± 42.6 ND
AZM+ 300.4 ± 35.9† 251.9 ± 43.3 ND
LPS 48 h AZM- 166.9 ± 19.6 40.5 ± 9.7 25.2 ± 3.2
AZM+ 220.1 ± 26.9 14.2 ± 3.1* 30.2. ± 4.4
WT LPS 3 h AZM- 3933.3 ± 264.6 3805.2 ± 355.6 ND
AZM+ 4254.2 ± 142.0 4368.5 ± 362.5 ND
LPS 24 h AZM- 169.8 ± 35.3 368.9 ± 84.6 ND
AZM+ 230.0 ± 31.9 361.6 ± 29.9 ND
LPS 48 h AZM- 328.1 ± 13.5 114.9 ± 8.0 40.5 ± 6.4
AZM+ 340.0 ± 10.1 111.0 ± 11.1 36.7 ± 2.2
Values are means ± SEM for 6–9 animals per each of the 12 subgroups from the same experiment as that used to generate Table 3. *p < 0.05; †p < 
0.005 and ‡p < 0.0005 for comparison of corresponding mean value vs. that obtained for the same parameter at the same time point without pre-
treatment with azithromycin. ND = below corresponding detectable levels.Page 10 of 13
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Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/134spontaneous abnormality in CF lung disease leading to
exacerbation of immune responses when inflammation is
acutely induced. Azithromycin reduces some lung inflam-
mation outcome measures in CF mice. We postulate that
some of the benefits of azithromycin treatment in CF
patients is due to modulating lung inflammation proba-
bly by reducing, at least partly, cellular infiltration and
pro-inflammatory cytokine expression.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
RL performed animal studies and biochemical analyses
and helped drafting the manuscript.
FH contributed to the study design, the evaluation of data
and the preparation of the manuscript.
TL designed and coordinated the study.
MD, EM performed pathological studies.
PL, JL, PW contributed to the study design.
DL, BJS revised the manuscript.
All authors have read the manuscript and approved the
final manuscript.
Acknowledgements
This work was funded by the French CF Association (VLM).
References
1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK,
Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic
fibrosis gene: genetic analysis.  Science 1989, 245:1073-1080.
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak
Z, Zielinski J, Lok S, Plavsic N, Chou JL: Identification of the cystic
fibrosis gene: cloning and characterization of complemen-
tary DNA.  Science 1989, 245:1066-1073.
3. Stutts MJ, Rossier BC, Boucher RC: Cystic fibrosis transmem-
brane conductance regulator inverts protein kinase A-medi-
ated regulation of epithelial sodium channel single channel
kinetics.  J Biol Chem 1997, 272:14307-14340.
4. Mohler PJ, Kreda SM, Boucher RC, Sudol M, Stutts MJ, Milgram SL:
Yes-associated protein 65 localizes p62(cYes) to the apical
compartment of airway epithelia by association with EBP50.
J Cell Biol 1999, 147:879-890.
5. Ismailov II, Awayda MS, Jovov B, Berdiev BK, Fuller CM, Dedman JR,
Kaetzel MA, Benos DJ: Regulation of epithelial sodium channels
by the cystic fibrosis transmembrane conductance regula-
tor.  J Biol Chem 1996, 271:4725-4732.
6. Schwiebert EM, Morales MM, Devidas S, Egan ME, Guggino WB:
Chloride channel and chloride conductance regulator
domain of CFTR, the cystic fibrosis transmembrane con-
ductance regulator.  Proc Natl Acad Sci USA 1998, 95:2674-2679.
7. Lukacs GL, Mohamed A, Kartner N, Chang X-B, Riordan JR, Grinstein
S: Conformational maturation of CFTR but not its mutant
counterpart (ΔF508) occurs in the endoplasmic reticulum
and requires ATP.  EMBO J 1994, 13:6076-6086.
8. Stern RC: The diagnosis of cystic fibrosis.  N Engl J Med 1997,
336:487-491.
9. Pamukcu A, Bush A, Buchdahal R: Effects of P. aeruginosa coloni-
zation on lung function and anthropomorphic variables in
children with cystic fibrosis.  Pediatr Pulmonol 1995, 19:10-15.
10. Henry RL, Mellis CM, Petrovic L: Mucoid Pseudomonas aerugi-
nosa is a marker of poor survival in cystic fibrosis.  Pediatr Pul-
monol 1992, 12:158-161.
11. Chmiel JF, Konstan MW: Anti-inflammatory medications for
cystic fibrosis lung disease: selecting the most appropriate
agent.  Treat Respir Med 2005, 4:255-273.
12. Dinwiddie R: Anti-inflammatory therapy in cystic fibrosis.  J
Cystic Fibrosis 2005, 4:45-48.
13. Jaffé A, Francis J, Rosenthal M, Bush A: Long-term azithromycin
may improve lung function in children with cystic fibrosis.
Lancet 1998, 351:420.
14. Wolter J, Seeney S, Bowler S, Masel P, McCornack J: Effect of long
term treatment with azithromycin on disease parameters in
cystic fibrosis: a randomised trial.  Thorax 2002, 57:212-216.
15. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M: Long term azithro-
mycin in children with cystic fibrosis: a randomised, placebo-
controlled crossover trial.  Lancet 2002, 360:978-984.
16. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL,
Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd,
Macrolide Study Group: Azithromycin in patients with cystic
fibrosis chronically infected with Pseudomonas aeruginosa: a
randomised controlled trial.  JAMA 2003, 290:1749-1756.
17. Gillis RI, Iglewski BH: Azithromycin retards Pseudomonas aer-
uginosa biofilm formation.  J Clin Microbiol 2004, 42:5842-5845.
18. Kita MA, Sawari M, Oku D Hamuro A, Mikasa K, Konishi M, Emoto
M, Takeuchi S, Narita N, Kashiba S: Suppression of virulence fac-
tors of Pseudomonas aeruginosa by erythromycin.  J Antimi-
crob Chemother 1991, 27:273-284.
19. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunga T,
Ohno A, Miyazaki S, Yamaguchi K: Direct evidence for antipseu-
domonal activity of macrolides: exposure dependent bacte-
ricidal activity and inhibition of protein synthesis by
erythromycin, clarithromycin and azithromycin.  Antimicrob
Agents Chemother 1996, 40:2271-2275.
20. Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K,
Ohno H, Miyazaki Y, Hirakata Y, Mizuta Y, Kadota J, Iglewski BH,
Kohno S: Azithromycin exhibits bactericidal effects on Pseu-
domonas aeruginosa through interaction with outer mem-
brane.  Antimicrob Agents Chemother 2005, 49:1377-1380.
21. Pier G, Grout M, Zaidi TS: Cystic fibrosis transmembrane con-
ductance regulator is an epithelial cell receptor for
clearence of Pseudomonas aeruginosa from the lung.  Proc
Natl Acad Sci USA 1997, 94:12088-12093.
22. Schroeder TH, Lee MM, Yacono PW, Cannon CL, Gerçeker AA,
Golan DE, Pier GB: CFTR is a pattern recognition molecule
that extracts Pseudomonas aeruginosa LPS from the outer
membrane into epithelial cells and activates NF-kB translo-
cation.  Proc Natl Acad Sci USA 2002, 99:6907-6912.
23. Pier GB: CFTR mutations and host susceptibility to Pseu-
domonas aeruginosa lung function.  Curr Opin Microbiol 2002,
5:81-86.
24. van Doorninck JH, French PJ, Verbeek E, Peters RHPC, Morreau H,
Bijman J, Scholte BJ: A mouse model for the cystic fibrosis
ΔF508 mutation.  EMBO J 1995, 14:4403-4411.
25. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Ill-
gen-Wilcke B, FELASA (Federation of European Laboratory Animal
Science Associations Working Group on Health Monitoring of
Rodent and Rabbit Colonies: Recommendation for the health
monitoring of rodent and rabbit colonies in breeding and
experimental units.  Lab Anim 2002, 36:20-42.
26. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH: Dual roles of
IL-4 in lung injury and fibrosis.  J Immunol 2003, 170:2083-2092.
27. Arras M, Huaux F, Vink A, Delos M, Coutelier JP, Many MC, Barbarin
V, Renauld JC, Lison D: Interleukin-9 reduces lung fibrosis and
type 2 immune polarization induced by silica particles in a
murine model.  Am J Respir Cell Mol Biol 2001, 24:368-375.
28. Naito Y, Yoshikawa T, Matsuyama K, Yagi N, Arai M, Nakamura Y,
Kaneko T, Yoshida N, Kondo M: Neutrophils, lipid peroxidation,
and nitric oxide in gastric reperfusion injury in rats.  Free Radic
Biol Med 1998, 24:494-502.Page 11 of 13
(page number not for citation purposes)
Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/13429. Lasfargues G, Lardot C, Delos M, Lauwerys R, Lison D: The delayed
lung responses to single and repeated intratracheal adminis-
tration of pure cobalt and hard metal powder in the rat.  Envi-
ron Res 1995, 69:108-21.
30. Hoiby H: Diffuse panbrochiolitis and cystic fibrosis: East
meets West.  Thorax 1994, 49:531-532.
31. Koyama H, Geddes DM: Erythromycin and diffuse panbronchi-
olitis.  Thorax 1997, 52:915-918.
32. Jaffe A, Bush A: Anti-inflammatory effects of macrolides in
lung disease.  Pediatr Pulmonol 2001, 31:464-473.
33. Pradal U, Delmarco A, Morganti M, Cipolli M, Mini E, Cazzola G:
Long-term azithromycin in cystic fibrosis: another possible
mechanism of action?  J Chemother 2005, 17:393-400.
34. Barker PM, Gillie DJ, Schechter MS, Rubin BK: Effect of macrolides
on in vivo transport across cystic fibrosis nasal epithelium.
Am J Respir Crit Care Med 2005, 1714:868-871.
35. Equi AC, Davies JC, Painter H, Hyde S, Bush A, Geddes DM, Alton
EW: Exploring the mechanisms of macrolides in cystic fibro-
sis.  Respir Med 2006, 100:687-697.
36. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC,
Smithies O, Koller BH: An animal model for cystic fibrosis
made by gene targeting.  Science 1992, 257:1083-1088.
37. Dorin JR, Dickinson P, Alton EW, Smith SN, Geddes DM, Stevenson
BJ: Cystic fibrosis in the mouse by targeted insertional muta-
genesis.  Nature 1992, 359:211-215.
38. Delaney SJ, Alton EW, Smith SN, Lunn DP, Farley R, Lovelock PK,
Thomson SA, Hume DA, Lamb D, Porteus DJ, Dorin JR, Wainwright
BJ: Cystic fibrosis mice carrying the missense mutation
G551D replicate human genotype-phenotype correlations.
EMBO J 1996, 15:955-963.
39. Colledge WH, Abelia BS, Southern KW, Ratcliff R, Jiang C, Cheng SH,
MacVinish LJ, Anderson JR, Cuthbert AW, Evans MJ: Generation
and characterization of a delta F508 cystic fibrosis mouse
model.  Nat Genet 1995, 10:445-452.
40. Zeiher BG, Eichwald E, Zabner J, Smith JJ, Puga AP, McCray PB Jr,
Capecchi MR, Welsh MJ, Thomas KR: A mouse model for the
delta F508 allele of cystic fibrosis.  J Clin Invest 1995,
96:2051-2064.
41. Durie PR, Kent G, Phillips MJ, Ackerley CA: Characteristic multi-
organ pathology of cystic fibrosis in a long-living cystic fibro-
sis transmembrane regulator knockout murine model.  Am J
Pathol 2004, 164:1481-1493.
42. Kent G, Iles R, Bear CE, Huan L-J, Griesenbach U, McKerlie C, Frn-
dova H, Ackerley C, Gosselin D, Radzioch D, O'Brodovich H, Tsui L-
C, Buchwald M, Tanswell AK: Lung disease in mice with cystic
fibrosis.  J Clin Invest 1997, 100:3060-3069.
43. Zahm JM, Gaillard D, Dupuit F, Hinnarasky J, Porteous D, Dorin JR,
Puchelle E: Early alterations in airway mucociliary clearence
and inflammation of the lamina propria in CF mice.  Am J Phys-
iol 1997, 272:C853-859.
44. van Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB,
Ferkol T: Excessive inflammatory response of cystic fibrosis
mice to bronchopulmonary infection with Pseudomonas
aeruginosa.  J Clin Invest 1997, 100:2810-2815.
45. Scholte BJ, Davidson DJ, Wilke M, De Jonge HR: Animal models of
cystic fibrosis.  J Cyst Fibros 2004, 3:183-190.
46. Grubb BR, Boucher RC: Pathophysiology of gene-targeted
mouse models for cystic fibrosis.  Physiol Rev 1999, 79:S193-S214.
47. van Heeckeren A, Schluchter MD, Xue W, Davis PB: Response to
acute lung infection with mucoid Pseudomonas aeruginosa
in cystic fibrosis mice.  Am J Respir Crit Care Med 2006,
173:288-296.
48. Schroeder T, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB:
Transgenic cystic fibrosis mice exhibit reduced early
clearence of Pseudomonas aeruginosa from the respiratory
tract.  J Immunol 2001, 166:7410-7418.
49. Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas
SO, Canon CL, Ausubel FM, Pier GB: Hypersusceptibility of cystic
fibrosis mice to chronic pseudomonas aeruginosa oropha-
ryngeal colonization and lung infection.  Proc Natl Acad Sci USA
2003, 100:1949-1954.
50. Yu H, Nasr SZ, Deretic V: Innate lung defenses and compro-
mised Pseudomonas aeruginosa clearance in the malnour-
ished mouse model of respiratory infections in cystic fibrosis.
Infect Immun 2000, 68:2142-2147.
51. van Heeckeren AM, Schluchter M, Xue L, Alvarez J, Freedman S, St
George J, Davis PB: Nutritional effects on host response to lung
infections with mucoid Paseudomonas aeruginosa in mice.
Infect Immun 2004, 72:1479-1489.
52. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW:
Early pulmonary inflammation in infants with cystic fibrosis.
Am J Respir Crit Care Med 1995, 151:1075-1082.
53. Balough KM, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick
R: The relationship between infection and inflammation in
the early stages of lung disease from cystic fibrosis.  Pediatr Pul-
monol 1995, 20:63-70.
54. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW: Nasal and
bronchoalveolar lavage fluid cytokines in early cystic fibrosis.
J Infect Dis 1997, 175:638-647.
55. Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot J,
Péault B, Puchelle E: Inflammation and infection in naive human
cystic fibrosis airway grafts.  Am J Respir Cell Mol Biol 2000,
23:121-127.
56. Armstrong DS, Hook SM, Jamsen KM, Nixon GM, Carzino R, Carlin
JB, Robertson CF, Grimwood K: Lower airway inflammation in
infants with cystic fibrosis detected by newborn screening.
Pediatr Pulmonol 2005, 40:500-510.
57. Konstan MW, Hilliard KA, Norvell TM, Berger M: Bronchoalveolar
lavage findings in cystic fibrosis patients with stable, clinically
mild lung disease suggest ongoing infection and inflamma-
tion.  Am J Respir Crit Care Med 1994, 150:448-454.
58. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan
PD: Lower respiratory tract infection and inflammation in
infants with newly diagnosed cystic fibrosis.  BMJ 1995,
310:1571-1572.
59. Bonfield TL, Konstan MW, Berger M: Altered respiratory epithe-
lial cell cytokine production in cystic fibrosis.  J Allerg Clin Immu-
nol 1999, 104:72-78.
60. Tabary O, Zahm JM, Hinnrasky J, Couétil JP, Cornillet P, Guenounou
, Gaillard D, Puchelle E, Jacquot J: Selective up-regulation of
chemokine IL-8 expression in cystic fibrosis bronchial gland
cells in vivo and in vitro.  Am J Pathol 1998, 153:921-930.
61. Kammouni W, Figarella C, Marchand S, Merten M: Altered
cytokine production by cystic fibrosis tracheal gland serous
cells.  Infect Immun 1997, 65:5176-5183.
62. Corvol H, Fitting C, Chadelat K, Jacquot J, Tabary O, Boule M, Cavail-
lon JM, Clement A: Distinct cytokine production by lung and
blood neutrophils from children with cystic fibrosis.  Am J Phys-
iol Lung Cell Mol Physiol 2003, 284:L997-1003.
63. Matheson NR, Wong PS, Travis J: Enzymatic inactivation of
human alpha-1-antitripsin inhibitor by neutrophil myeloper-
oxidase.  Biochem Biophys Res Commun 1979, 88:402-409.
64. Clark RA, Stone PJ, Hag AE, Calore JD, Franzblau C: Myeloperoxy-
dase-catalysed inactivation of α1-proteinase inhibitor by
human neutrophils.  J Biol Chem 1981, 256:3348-3353.
65. Heinecke JW, Li W, Francis GA, Goldstein JA: Tyrosyl radical gen-
erated by myeloperoxidase catalyzes the oxidative cross-
linking of proteins.  J Clin Invest 1993, 91:2866-2872.
66. Garner HP, Phillips JR, Herron JG, Severson SJ, Mila CE, Regelman
WE: Peroxidase activity within circulating neutrophils corre-
lates with pulmonary phenotype in cystic fibrosis.  J Lab Clin
Med 2004, 144:127-133.
67. Koller DY, Gotz M, Wojnarowski C, Eichler I: Relationship
between disease severity and inflammatory markers in
cystic fibrosis.  Arch Dis Child 1996, 75:498-501.
68. Johnson LG, Vanhook MK, Coyne CB, Haykal-Coates N, Gavett SH:
Safety and efficiency of modulating paracellular permeability
to enhance airway epithelial gene transfer in vivo.  Hum Gene
Ther 2003, 14:729-747.
69. Ferretti S, Bonneau O, Dubois G, Jones CE, Trifilieff A: IL-17, pro-
duced by lymphocytes and neutrophils, is necessary for
lipopolysaccharide-induced airway neutrophilia: IL-15 as a
possible trigger.  J Immunol 2003, 170:2106-2112.
70. Freedman SD, Weinstein D, Blanco PG, Martinez-Clark P, Urman S,
Zaman M, Morrow JD, Alvarez JG: Characterization of LPS-
induced lung inflammation in cftr-/- mice and the effect of
docosahexaenoic acid.  J Appl Physiol 2002, 92:2169-2176.
71. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB,
Ghnaim H, Berger M: Inflammatory cytokines in cystic fibrosis
lungs.  Am J Respir Crit Care Med 1995, 152:2111-2118.Page 12 of 13
(page number not for citation purposes)
Respiratory Research 2006, 7:134 http://respiratory-research.com/content/7/1/134Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
72. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger
M: Normal bronchial epithelial cells constitutively produce
the anti-inflammatory cytokine interleukin-10, which is
downregulated in cystic fibrosis.  Am J Respir Cell Mol Biol 1995,
13:257-261.
73. Saadane A, Soltys J, Berger M: Role of IL-10 deficiency in exces-
sive nuclear factor-kppaB activation and lung inflammation
in cystic fibrosis transmembrane conductance regulator
knockout mice.  J Allergy Clin Immunol 2005, 115:405-411.
74. Chmiel JF, Konstan MW, Knesebeck JE, Hilliard JB, Bonfield TL, Daw-
son DV, Berger M: IL-10 attenuates excessive inflammation in
chronic Pseudomonas infection in mice.  Am J Respir Crit Care
Med 1999, 160:2040-2047.
75. Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Kirchner HL, Berger
M: Prolonged inflammatory response to acute Pseudomonas
challenge in interleukin-10 knockout mice.  Am J Respir Crit Care
Med 2002, 165:1176-1181.
76. Saadane A, Soltys J, Berger M: Role of IL-10 deficiency in exces-
sive nuclear factor-kappaB activation and lung inflammation
in cystic fibrosis transmembrane conductance regulator
knockout mice.  J Allergy Clin Immunol 2005, 115:405-411.
77. Tabary O, Escotte S, Couétil JP, Hubert D, Dusser D, Puchelle E, Jac-
quot J: High susceptibility for cystic fibrosis human airway
gland cells to produce IL-8 through the IκB kinase alpha
pathway in response to extracellular NaCl content.  J Immunol
2000, 164:3377-3384.
78. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcrip-
tion factor in chronic inflammatory diseases.  N Engl J Med
1997, 336:1066-1071.
79. Wright JG, Christman JW: The role of nuclear factor kappa B in
the pathogenesis of pulmonary diseases: implications for
therapy.  Am J Respir Med 2003, 2:211-219.
80. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han
E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M: Absolute bioavail-
ability and intracellular pharmacokinetics of azithromycin in
patients with cystic fibrosis.  Antimicrob Agents Chemother 2005,
49:5013-5017.
81. Everard ML, Sly P, Brenan S, Ryan G: Macrolide antibiotics in dif-
fuse panbronchiolitis and in cystic fibrosis.  Eur Respir J 1997,
10:2926.
82. Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda
K, Hershenson MB, Standiford TJ: Azithromycin blocks neu-
trophil recruitment in Pseudomonas endobronchial infec-
tion.  Am J Respir Crit Care Med 2004, 170:1331-1339.
83. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman JM,
Standiford : Neutralization of IL-10 increases survival in a
murine model of Klebsiella pneumonia.  J Immunol 1995,
155:722-729.
84. van der Poll T, Marchant A Keogh CV, Goldman M, Lowry SF: Inter-
leukin-10 impairs host defense in murine pneumococcal
pneumonia.  J infect Dis 1996, 174:994-1000.Page 13 of 13
(page number not for citation purposes)
